Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosuvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDE6D | O43924 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.83 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.83 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosuvastatin SCHEMBL28393539 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240432 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL32686257 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL41433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL3938301 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL154400 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL16995485 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL240433 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL8268193 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Rosuvastatin SCHEMBL29722976 | 1.00 | HMGCR (1.00) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 49380 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144789-A1 | WOUND TREATMENTS AND COMPOSITIONS | CMPD LICENSING, LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094667-A | Formulations and uses of ROCK2 inhibitors for ALS | — | 2026-05-26 | — | — | CN | claimed |
| US-12636273-B2 | Compositions for pathogenesis-directed therapy and treatments of skin diseases and disorders | YALE UNIVERSITY (US) | 2026-05-26 | — | — | US | claimed |
| US-12640239-B2 | Functional biomarkers for statin therapy in age-related macular degeneration (AMD) | APELIOTUS TECHNOLOGIES, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-117085011-B | Pharmaceutical composition of ezetimibe and HMG-CoA reductase inhibitor | ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD. (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4745160-A1 | METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| CN-117890509-B | Ezetimibe rosuvastatin calcium tablet dissolution curve detection method with distinguishing force | 江西施美药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-3700518-B1 | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH A COMPOSITION COMPRISING ICOSAPENT ETHYL | AMARIN PHARMACEUTICALS IE LTD (IE) | 2026-05-13 | — | — | EP | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2001096347-A1 | HMG-CoA REDUCTASE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6316460-B1 | CONTAINING A HEPTENOIC ACID DERIVATIVE AND A TRIBASIC PHOSPHATE SALT AS A STABILIZER; HMG-COA REDUCTASE INHIBITOR | ASTRAZENECA AB (SE) | 2001-11-13 | — | — | US | claimed |
| EP-1150679-A1 | USE OF CHOLESTEROL-LOWERING AGENT | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | claimed |
| WO-2001076573-A2 | COMBINATION OF AT LEAST TWO COMPOUNDS SELECTED FROM AN AT1-RECEPTOR ANTAGONIST OR AN ACE INHIBITOR OR A HMG-CO-A REDUCTASE INHIBITOR GROUPS | NOVARTIS AG (CH) | 2001-10-18 | — | — | WO | claimed |
| WO-2001074394-A1 | NEW COMBINATION OF A BETABLOCKER AND A CHOLESTEROL-LOWERING AGENT | ASTRAZENECA AB (SE) | 2001-10-11 | — | — | WO | claimed |
| WO-2001060804-A1 | CRYSTALLINE SALTS OF 7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL]-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID | ASTRAZENECA AB (SE) | 2001-08-23 | — | — | WO | claimed |
| US-RE37314-E1 | Pyrimidine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | claimed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| EP-0521471-B1 | Pyrimidine derivatives as HMG-CoA reductase inhibitors | SHIONOGI & CO (JP) | 2000-10-25 | — | — | EP | claimed |
| WO-2000045819-A1 | USE OF CHOLESTEROL-LOWERING AGENT | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |